Literature DB >> 28418672

A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.

Jianliang Shen1, Han-Cheon Kim1, Joy Wolfram1,2, Chaofeng Mu1, Wei Zhang3, Haoran Liu1, Yan Xie1,4, Junhua Mai1, Hang Zhang3, Zhi Li1, Maria Guevara1, Zong-Wan Mao3, Haifa Shen1,5.   

Abstract

Ruthenium coordination complexes have the potential to serve as novel theranostic agents for cancer. However, a major limitation in their clinical implementation is effective tumor accumulation. In this study, we have developed a liposome-based theranostic nanodelivery system for [Ru(phen)2dppz](ClO4)2 (Lipo-Ru). This ruthenium polypyridine complex emits a strong fluorescent signal when incorporated in the hydrophobic lipid bilayer of the delivery vehicle or in the DNA helix, enabling visualization of the therapeutic agent in tumor tissues. Incubation of MDA-MB-231 breast cancer cells with Lipo-Ru induced double-strand DNA breaks and triggers apoptosis. In a mouse model of triple-negative breast cancer, treatment with Lipo-Ru dramatically reduced tumor growth. Biodistribution studies of Lipo-Ru revealed that more than 20% of the injected dose accumulated in the tumor. These results suggest that Lipo-Ru could serve as a promising theranostic platform for cancer.

Entities:  

Keywords:  Liposome; nanoplatform; ruthenium polypyridine complex; theranostic; triple-negative breast cancer

Mesh：

Substances：

Year:  2017        PMID： 28418672      PMCID： PMC5484597          DOI： 10.1021/acs.nanolett.7b00132

Source DB:  PubMed          Journal:  Nano Lett        ISSN： 1530-6984            Impact factor:   11.189


  42 in total

Review 1.  Ruthenium(II) polypyridyl complexes and DNA--from structural probes to cellular imaging and therapeutics.

Authors:  Martin R Gill; Jim A Thomas
Journal:  Chem Soc Rev       Date:  2012-02-07       Impact factor: 54.564

Review 2.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

3.  Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks.

Authors:  Arkady Celeste; Oscar Fernandez-Capetillo; Michael J Kruhlak; Duane R Pilch; David W Staudt; Alicia Lee; Robert F Bonner; William M Bonner; André Nussenzweig
Journal:  Nat Cell Biol       Date:  2003-07       Impact factor: 28.824

4.  Induction of cell death by ternary copper(II) complexes of L-tyrosine and diimines: role of coligands on DNA binding and cleavage and anticancer activity.

Authors:  Sethu Ramakrishnan; Venugopal Rajendiran; Mallayan Palaniandavar; Vaiyapuri Subbarayan Periasamy; Bangalore Suresh Srinag; Hanumanthappa Krishnamurthy; Mohammad Abdulkader Akbarsha
Journal:  Inorg Chem       Date:  2009-02-16       Impact factor: 5.165

Review 5.  Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.

Authors:  Anand Rajeswaran; Andreas Trojan; Bernard Burnand; Massimo Giannelli
Journal:  Lung Cancer       Date:  2007-08-27       Impact factor: 5.705

6.  Hesperetin Liposomes for Cancer Therapy.

Authors:  Joy Wolfram; Bronwyn Scott; Kathryn Boom; Jianliang Shen; Carlotta Borsoi; Krishna Suri; Rossella Grande; Massimo Fresta; Christian Celia; Yuliang Zhao; Haifa Shen; Mauro Ferrari
Journal:  Curr Drug Deliv       Date:  2016       Impact factor: 2.565

Review 7.  Targeted therapy for triple-negative breast cancer: where are we?

Authors:  Michael J Duffy; Patricia M McGowan; John Crown
Journal:  Int J Cancer       Date:  2012-06-07       Impact factor: 7.396

Review 8.  Exploring the cellular accumulation of metal complexes.

Authors:  Cindy A Puckett; Russell J Ernst; Jacqueline K Barton
Journal:  Dalton Trans       Date:  2009-12-23       Impact factor: 4.390

9.  Cyclodextrin and polyethylenimine functionalized mesoporous silica nanoparticles for delivery of siRNA cancer therapeutics.

Authors:  Jianliang Shen; Han-Cheon Kim; Hua Su; Feng Wang; Joy Wolfram; Dickson Kirui; Junhua Mai; Chaofeng Mu; Liang-Nian Ji; Zong-Wan Mao; Haifa Shen
Journal:  Theranostics       Date:  2014-02-15       Impact factor: 11.556

Review 10.  New trends for metal complexes with anticancer activity.

Authors:  Pieter C A Bruijnincx; Peter J Sadler
Journal:  Curr Opin Chem Biol       Date:  2008-01-25       Impact factor: 8.822
View more
  19 in total

1.  Amino-Functionalized Mesoporous Silica Nanoparticle-Encapsulated Octahedral Organoruthenium Complex as an Efficient Platform for Combatting Cancer.

Authors:  Marina Martínez-Carmona; Quy P Ho; Jérémy Morand; Ana García; Enrique Ortega; Luiza C S Erthal; Eduardo Ruiz-Hernandez; M Dolores Santana; José Ruiz; Maria Vallet-Regí; Yurii K Gun'ko
Journal:  Inorg Chem       Date:  2020-07-06       Impact factor: 5.165

Review 2.  The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Authors:  Leli Zeng; Pranav Gupta; Yanglu Chen; Enju Wang; Liangnian Ji; Hui Chao; Zhe-Sheng Chen
Journal:  Chem Soc Rev       Date:  2017-10-02       Impact factor: 54.564

Review 3.  Organotropic drug delivery: Synthetic nanoparticles and extracellular vesicles.

Authors:  Sara Busatto; Anthony Pham; Annie Suh; Shane Shapiro; Joy Wolfram
Journal:  Biomed Microdevices       Date:  2019-04-15       Impact factor: 2.838

Review 4.  Current advances in the use of exosomes, liposomes, and bioengineered hybrid nanovesicles in cancer detection and therapy.

Authors:  Anubhab Mukherjee; Bharti Bisht; Suman Dutta; Manash K Paul
Journal:  Acta Pharmacol Sin       Date:  2022-04-04       Impact factor: 6.150

5.  Novel iridium(III) iminopyridine complexes: synthetic, catalytic, and in vitro anticancer activity studies.

Authors:  Deliang Kong; Meng Tian; Lihua Guo; Xicheng Liu; Shumiao Zhang; Yameng Song; Xin Meng; Shu Wu; Lingzi Zhang; Zhe Liu
Journal:  J Biol Inorg Chem       Date:  2018-06-11       Impact factor: 3.358

Review 6.  Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer.

Authors:  Nazia Nayeem; Maria Contel
Journal:  Chemistry       Date:  2021-05-05       Impact factor: 5.020

7.  111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells.

Authors:  Martin R Gill; Jyothi U Menon; Paul J Jarman; Joshua Owen; Irini Skaripa-Koukelli; Sarah Able; Jim A Thomas; Robert Carlisle; Katherine A Vallis
Journal:  Nanoscale       Date:  2018-06-07       Impact factor: 8.307

8.  Investigation of the Effects and Mechanisms of Anticancer Action of a Ru(II)-Arene Iminophosphorane Compound in Triple Negative Breast Cancer Cells.

Authors:  Nazia Nayeem; Arefa Yeasmin; Samantha N Cobos; Ali Younes; Karen Hubbard; Maria Contel
Journal:  ChemMedChem       Date:  2021-08-24       Impact factor: 3.466

Review 9.  Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.

Authors:  Arya Bhushan; Andrea Gonsalves; Jyothi U Menon
Journal:  Pharmaceutics       Date:  2021-05-14       Impact factor: 6.321

Review 10.  Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics.

Authors:  Shengzhe Zhao; Xujiang Yu; Yuna Qian; Wei Chen; Jianliang Shen
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.